Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective Randomized Open Label Blinded Endpoint Multicenter Study in Patients With Coronary Artery Disease to Assess the LDL Lowering Effect of Switching to Ezetimibe (+) Simvastatin for Cholesterol Lowering, Compared the Dose of the Statin Used.
Brief Summary: In patients with coronary artery disease and a LDL-C level between 2.5 mmol/L and 5.0 mmol/L on a stable (\> 4 weeks) statin starting dose (simvastatin 20 mg or atorvastatin 10 mg), investigate what the LCL-C lowering efficacy is of doubling the statin dose (to 40 mg simvastatin or 20 mg atorvastatin) versus a combination tablet of ezetimibe 10 mg plus simvastatin 20 mg once daily for 12 weeks. It is postulated that more patients reach their LDL-C treatment goal with the combination tablet compared to doubling the starting dose. Furthermore, the effect of both treatment regimens on other lipid parameters, safety and LDL-subfractions will be measured.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Simvastatin 20mg plus Ezetimibe 10mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Simvastatin 20 mg, Drug: Ezetimibe 10mg | Arm Label: Simvastatin 20mg; Type: OTHER; Interventions: Drug: Simvastatin 20 mg | Intervention Type: DRUG; Name: Simvastatin 20 mg; Assigned to Arm(s): Simvastatin 20mg, Simvastatin 20mg plus Ezetimibe 10mg | Intervention Type: DRUG; Name: Ezetimibe 10mg; Assigned to Arm(s): Simvastatin 20mg plus Ezetimibe 10mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: SANDS Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: SANDS Intervention Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: FDA approved drugs to treat blood pressure and cholesterol | Intervention Type: DRUG; Name: FDA approved drugs to treat blood pressure and cholesterol; Assigned to Arm(s): SANDS Intervention Group
C: Arm Label: Placebo Q2W; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo to Evolocumab, Other: Placebo to Ezetimibe | Arm Label: Placebo QM; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo to Evolocumab, Other: Placebo to Ezetimibe | Arm Label: Ezetimibe (Q2W); Type: ACTIVE_COMPARATOR; Interventions: Drug: Ezetimibe, Biological: Placebo to Evolocumab | Arm Label: Ezetimibe (QM); Type: ACTIVE_COMPARATOR; Interventions: Drug: Ezetimibe, Biological: Placebo to Evolocumab | Arm Label: Evolocumab Q2W; Type: EXPERIMENTAL; Interventions: Biological: Evolocumab, Other: Placebo to Ezetimibe | Arm Label: Evolocumab QM; Type: EXPERIMENTAL; Interventions: Biological: Evolocumab, Other: Placebo to Ezetimibe | Intervention Type: BIOLOGICAL; Name: Evolocumab; Assigned to Arm(s): Evolocumab Q2W, Evolocumab QM | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): Ezetimibe (Q2W), Ezetimibe (QM) | Intervention Type: BIOLOGICAL; Name: Placebo to Evolocumab; Assigned to Arm(s): Ezetimibe (Q2W), Ezetimibe (QM), Placebo Q2W, Placebo QM | Intervention Type: OTHER; Name: Placebo to Ezetimibe; Assigned to Arm(s): Evolocumab Q2W, Evolocumab QM, Placebo Q2W, Placebo QM
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: simvastatin, Drug: atorvastatin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: ezetimibe (+) simvastatin | Intervention Type: DRUG; Name: ezetimibe (+) simvastatin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: simvastatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): 1

Answer: D